CFTR and lung disorder: Most participants had mild-to-moderate lung disease, as shown by ppFEV1.Those receiving CFTR modulators versus not had lower lung function (ppFEV1, mean [SD]: 61.6 [9.0] versus 73.1 [7.4], respectively), a higher use of pancreatic enzymes (n [%]: 17 [81.0] versus 5 [62.5], respectively), and higher use of chronic antibiotics (61.9% versus 50.0%, respectively) (Table 1).